Respiri Limited (ASX: $RSH) Quarterly Cash Flow and Activities Report

Respiri Limited (ASX: $RSH) has released its Appendix 4C quarterly cash flow and activities report for the 3-month period ended 30 June, 2024. The report highlights a record enrolment of 1,423 active patients on programs, representing a 4+ fold increase in patient numbers from the previous quarter. The company also doubled healthcare organization customers from 15 to 26 and reported record invoiced recurring revenues of AUD$195K, with AUD$99K in June. Respiri continues to scale US operations to manage current increased patient volume and forecast growth, with a new wearable device USA clinical study contract and protocol finalized, and the first patient enrolment expected in August 2024.

Executive Commentary on Growth and Future Outlook

The June 2024 quarter has been a significant inflection milestone for Respiri, with a substantial increase in patient numbers and healthcare organization clients. The company's differentiated service model has been well received by new partners and clients, leading to a forecasted significant growth in patient numbers. We are actively evaluating possible acquisition target businesses in this highly fragmented sector, which presents both restructuring procurement/efficiency cost savings and growth opportunities. Our strategic push into the value-based/risk share contracted space has seen executive leadership experience from this sector employed, making a significant impact on our progress. We are also finalizing new contracts in Hawaii and across the mainland, focusing on contracting major clients such as Payor/health insurers and IPAs/ACOs. We are confident in our ability to continue operations and meet our business objectives using equity raised from our planned US listing and an increase in revenues following the acquisition of Access Telehealth.

Summary of Quarterly Report and Outlook

Respiri's June 2024 quarterly report reflects a remarkable growth in patient numbers, healthcare organization clients, and invoiced recurring revenues. The company's differentiated service model has been well received, leading to a forecasted significant growth in patient numbers and a strong outlook for the future. Respiri anticipates breaking even in late 2024 by achieving the target of 9,000 patients or patient-revenue equivalents from other revenue generating programs. The company is actively evaluating possible acquisition target businesses in the highly fragmented sector and is confident in its ability to continue operations and meet its business objectives using equity raised from its planned US listing and an increase in revenues following the acquisition of Access Telehealth. The new wearable device clinical study contract and protocol have been finalized, with the first patient expected to be enrolled in August 2024, marking a significant step in the company's research and development endeavors.